PF-Atlas › Clinical Trials › NCT04533022
Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF
C21 · Phase 2
Registry ID
NCT04533022
Phase
Phase 2
Status
Completed
Drug / intervention
C21
Sponsor
Vicore Pharma AB
Start
2020-11-13
Enrollment
52
Locations
21
About this trial
This trial is a multi-centre, open-label, single-arm phase 2 trial investigating the safety, efficacy and pharmacokinetics of C21 in subjects with idiopathic pulmonary fibrosis.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT04533022 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.